Assessing Kymera Therapeutics (KYMR) Valuation After Equity Offering Losses And Leadership Change

Simply Wall St.02-27 05:37

Kymera Therapeutics (KYMR) has put several big issues on the table at once, combining fresh fourth quarter and full year 2025 losses with new equity issuance plans and a key leadership hire. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614071171?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-27 05:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614071171","market":"us","top_or_hot":-1,"title":"Assessing Kymera Therapeutics (KYMR) Valuation After Equity Offering Losses And Leadership Change","media":"Simply Wall St.","content":"<div>\n<p>Kymera Therapeutics (KYMR) has put several big issues on the table at once, combining fresh fourth quarter and full year 2025 losses with new equity issuance plans and a key leadership hire. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/assessing-kymera-therapeutics-kymr-valuation-after-equity-of\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Kymera Therapeutics (KYMR) Valuation After Equity Offering Losses And Leadership Change</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Kymera Therapeutics (KYMR) Valuation After Equity Offering Losses And Leadership Change\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 05:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/assessing-kymera-therapeutics-kymr-valuation-after-equity-of><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kymera Therapeutics (KYMR) has put several big issues on the table at once, combining fresh fourth quarter and full year 2025 losses with new equity issuance plans and a key leadership hire. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/assessing-kymera-therapeutics-kymr-valuation-after-equity-of\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/assessing-kymera-therapeutics-kymr-valuation-after-equity-of","article_id":"2614071171","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/assessing-kymera-therapeutics-kymr-valuation-after-equity-of","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614071171","pubTimestamp":1772141843,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Kymera Therapeutics (KYMR) has put several big issues on the table at once, combining fresh fourth quarter and full year 2025 losses with new equity issuance plans and a key leadership hire.\nSee our latest analysis for Kymera Therapeutics.\nDespite the larger reported losses and fresh equity plans, Kymera’s recent momentum has been strong, with a 27.61% 1 month share price return and a 156.45% 1 year total shareholder return, suggesting investors are reassessing both risk and potential.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EQR":"资产住宅公司","KYMR":"Kymera Therapeutics, Inc.","BK4215":"住宅房地产投资信托","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"评估Kymera Therapeutics(KYMR)在股票发行损失和领导层变动后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"KYMR":1.5},"content_text":"Kymera Therapeutics (KYMR) has put several big issues on the table at once, combining fresh fourth quarter and full year 2025 losses with new equity issuance plans and a key leadership hire. See our latest analysis for Kymera Therapeutics. Despite the larger reported losses and fresh equity plans, Kymera’s recent momentum has been strong, with a 27.61% 1 month share price return and a 156.45% 1 year total shareholder return, suggesting investors are reassessing both risk and potential. If this earnings update has you looking beyond a single name, it could be a good moment to see what else is moving in healthcare, including our screener of 30 healthcare AI stocks. With Kymera still reporting sizeable losses, fresh equity issuance on the table and the share price sitting below one widely watched fair value estimate of US$116.71, investors may question whether there is still upside potential or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 22.3% Undervalued Kymera’s widely followed narrative pegs fair value at about $116.71 per share, compared with the last close at $90.68, putting a premium spotlight on its long term potential.  The anticipated Phase II and III trials for their immunology pipeline aim to deliver biologics-like efficacy in oral form, which could enhance net margins by reducing manufacturing costs associated with biologics and potentially capturing a larger market share.  Read the complete narrative. Curious how an oral pipeline and rising revenue assumptions are used to justify that higher fair value and a very high future earnings multiple? The full narrative lays out the growth, margins and discount rate choices that have to line up for Kymera to reach that target. Result: Fair Value of $116.71 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on heavy R&D spend and partnership execution, so any setback in trials or collaborator pullback could quickly challenge that premium valuation story. Find out about the key risks to this Kymera Therapeutics narrative. Another Angle On Valuation That US$116.71 fair value leans heavily on long term earnings assumptions. If you look at Kymera’s current P/B of 7.7x instead, it screens a bit expensive next to US Biotechs at 2.7x and even its peer group at 7.6x. This raises a simple question: how much optimism is already in the price? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:KYMR P/B Ratio as at Feb 2026Next Steps If this feels finely balanced between optimism and caution, act while the details are fresh and weigh the trade off yourself with 2 key rewards and 4 important warning signs. Ready to spot your next opportunity? Kymera might be on your radar today, but you do not want to stop at a single idea when there are focused stock lists ready to review.  Start with resilience by checking companies that show consistent strength in their finances through our solid balance sheet and fundamentals stocks screener (41 results). Hunt for potential mispricing by scanning our 53 high quality undervalued stocks that match strong fundamentals with prices that may not fully reflect them. Aim for staying power and income by focusing on steady payers in our 15 dividend fortresses built for investors who care about cash returns.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Kymera Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614071171","isCrawlerRequest":true}